TTY Biopharm Company Limited (TPEX: 4105)

TTY Biopharm Company Statistics

Total Valuation

TTY Biopharm Company has a market cap or net worth of TWD 18.77 billion. The enterprise value is 19.09 billion.

Market Cap	18.77B
Enterprise Value	19.09B

Important Dates

The next estimated earnings date is Tuesday, March 11, 2025.

Earnings Date	Mar 11, 2025
Ex-Dividend Date	n/a

Share Statistics

TTY Biopharm Company has 248.65 million shares outstanding. The number of shares has increased by 0.14% in one year.

Current Share Class	n/a
Shares Outstanding	248.65M
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	11.44%
Owned by Institutions (%)	15.74%
Float	193.63M

Valuation Ratios

The trailing PE ratio is 16.81 and the forward PE ratio is 17.00.

PE Ratio	16.81
Forward PE	17.00
PS Ratio	3.22
PB Ratio	3.02
P/TBV Ratio	3.23
P/FCF Ratio	18.21
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.37, with an EV/FCF ratio of 18.52.

EV / Earnings	17.05
EV / Sales	3.28
EV / EBITDA	11.37
EV / EBIT	12.80
EV / FCF	18.52

Financial Position

The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.33.

Current Ratio	1.77
Quick Ratio	1.26
Debt / Equity	0.33
Debt / EBITDA	1.52
Debt / FCF	2.24
Interest Coverage	35.67

Financial Efficiency

Return on equity (ROE) is 17.29% and return on invested capital (ROIC) is 9.31%.

Return on Equity (ROE)	17.29%
Return on Assets (ROA)	8.08%
Return on Capital (ROIC)	9.31%
Revenue Per Employee	17.04M
Profits Per Employee	3.27M
Employee Count	342
Asset Turnover	0.57
Inventory Turnover	1.74

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.15% in the last 52 weeks. The beta is 0.19, so TTY Biopharm Company's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	-9.15%
50-Day Moving Average	73.65
200-Day Moving Average	76.15
Relative Strength Index (RSI)	67.44
Average Volume (20 Days)	415,530

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TTY Biopharm Company had revenue of TWD 5.83 billion and earned 1.12 billion in profits. Earnings per share was 4.49.

Revenue	5.83B
Gross Profit	3.41B
Operating Income	1.33B
Pretax Income	1.44B
Net Income	1.12B
EBITDA	1.52B
EBIT	1.33B
Earnings Per Share (EPS)	4.49

Balance Sheet

The company has 2.76 billion in cash and 2.31 billion in debt, giving a net cash position of 443.62 million or 1.78 per share.

Cash & Cash Equivalents	2.76B
Total Debt	2.31B
Net Cash	443.62M
Net Cash Per Share	1.78
Equity (Book Value)	6.97B
Book Value Per Share	25.00
Working Capital	2.54B

Cash Flow

In the last 12 months, operating cash flow was 1.12 billion and capital expenditures -91.40 million, giving a free cash flow of 1.03 billion.

Operating Cash Flow	1.12B
Capital Expenditures	-91.40M
Free Cash Flow	1.03B
FCF Per Share	4.15

Margins

Gross margin is 58.47%, with operating and profit margins of 22.86% and 19.22%.

Gross Margin	58.47%
Operating Margin	22.86%
Pretax Margin	24.79%
Profit Margin	19.22%
EBITDA Margin	26.07%
EBIT Margin	22.86%
FCF Margin	17.69%

Dividends & Yields

This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 4.65%.

Dividend Per Share	3.50
Dividend Yield	4.65%
Dividend Growth (YoY)	-45.31%
Years of Dividend Growth	1
Payout Ratio	77.23%
Buyback Yield	-0.14%
Shareholder Yield	4.51%
Earnings Yield	5.95%
FCF Yield	5.49%

Stock Splits

The last stock split was on August 13, 2014. It was a forward split with a ratio of 1.067.

Last Split Date	Aug 13, 2014
Split Type	Forward
Split Ratio	1.067

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a